Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilization

Cell Death and Disease

Volumn 6, Issue 4, 2015, Pages

  Wei, L ^a   Zhou, Y ^a   Qiao, C ^a   Ni, T ^a   Li, Z ^a   You, Q ^a   Guo, Q ^a   Lu, N ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; DOXORUBICIN; GLUCOSE; HEXOKINASE; HEXOKINASE II; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; OROXYLIN A; OXYGEN; PROTEIN; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; SIRTUIN 3; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; 5,7-DIHYDROXY-6-METHOXY-2-PHENYLCHROMEN-4-ONE; FLAVONOID; SIRT3 PROTEIN, HUMAN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DEACETYLATION; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FLAVONOIDS; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED BALB C; MICE, NUDE; SIRTUIN 3; SUPEROXIDE DISMUTASE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84989939219     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.86     Document Type: Article

References (46)

1. Hanahan D,Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev 2004; 4: 891-899.
3. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev 2008; 8: 705-713.
4. Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010; 20: 51-56.
5. Sluimer JC, Gasc JM, van Wanroij JL, Kisters N, Groeneweg M, Sollewijn Gelpke MD et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol 2008; 51: 1258-1265.
6. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177-185.
7. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460: 587-591.
8. Newman JC, He W, Verdin E. Mitochondrial protein acylation and intermediary metabolism: regulation by sirtuins and implications for metabolic disease. J Biol Chem 2012; 287: 42436-42443.
9. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010; 17: 41-52.
10. Giralt A, Villarroya F. SIRT3 a pivotal actor in mitochondrial functions: metabolism, cell death and aging. Biochem J 2012; 444: 1-10.
11. Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD et al. Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer 2006; 95: 1056-1061.
12. Chen Y, Zhang J, Lin Y, Lei Q, Guan KL, Zhao S et al. Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep 2010; 12: 534-541.
13. Bell EL, Klimova TA, Eisenbart J, Moraes CT, Murphy MP, Budinger GR et al. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J Cell Biol 2007; 177: 1029-1036.
14. Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell 2011; 19: 416-428.
15. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009; 8: 579-591.
16. Storz P. Forkhead homeobox type O transcription factors in the responses to oxidative stress. Antioxid Redox Signal 2011; 14: 593-605.
17. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest 2009; 119: 2758-2771.
18. Chen Y, Zhang J, Lin Y, Lei Q, Guan KL, Zhao S et al. Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep 2011; 12: 534-541.
19. Dai Q, Yin Y, Liu W, Wei L, Zhou Y, Li Z et al. Two p53-related metabolic regulators, TIGAR and SCO2, contribute to oroxylin A-mediated glucose metabolism in human hepatoma HepG2 cells. Int J Biochem Cell Biol 2013; 45: 1468-1478.
20. Wei L, Zhou Y, Dai Q, Qiao C, Zhao L, Hui H et al. Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma. Cell Death Dis 2013; 4: e601.
21. O'Donnell JL, Joyce MR, Shannon AM, Harmey J, Geraghty J, Bouchier-Hayes D. Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression. Cancer Treat Rev 2006; 32: 407-416.
22. Pastorino JG, Hoek JB. Regulation of hexokinase binding to VDAC. J Bioenerg Biomembr 2008; 40: 171-182.
23. Shaw RJ. Glucose metabolism and cancer. Curr Opin Cell Biol 2006; 18: 598-608.
24. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell 2010; 38: 864-878.
25. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 2004; 19: 176-182.
26. Snell CE, Turley H, McIntyre A, Li D, Masiero M, Schofield CJ et al. Proline-hydroxylated hypoxiainducible factor 1alpha (HIF-1alpha) upregulation in human tumours. PLoS One 2014; 9: e88955.
27. Kaelin WG Jr., Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008; 30: 393-402.
28. Hamanaka RB, Chandel NS. Mitochondrial reactive oxygen species regulate hypoxic signaling. Curr Opin Cell Biol 2009; 21: 894-899.
29. Cooper ML, Adami HO, Gronberg H, Wiklund F, Green FR, Rayman MP. Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk. Cancer Res 2008; 68: 10171-10177.
30. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab 2010; 12: 662-667.
31. Jacobs KM, Pennington JD, Bisht KS, Aykin-Burns N, Kim HS, Mishra M et al. SIRT3 interacts with the daf-16 homolog FOXO3a in the mitochondria, as well as increases FOXO3a dependent gene expression. Int J Biol Sci 2008; 4: 291-299.
32. Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci 2007; 97: 539-547.
33. Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C et al. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 2008; 99: 121-128.
34. Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL. SIRT3 and cancer: tumor promoter or suppressor? Biochim Biophys Acta 2011; 1816: 80-88.
35. Lawson M, Uciechowska U, Schemies J, Rumpf T, Jung M, Sippl W. Inhibitors to understand molecular mechanisms of NAD(+)-dependent deacetylases (sirtuins). Biochim Biophys Acta 2010; 1799: 726-739.
36. Bell EL, Emerling BM, Ricoult SJ, Guarente L. SirT3 suppresses hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS production. Oncogene 2011; 30: 2986-2996.
37. Xu M, Lu N, Sun Z, Zhang H, Dai Q, Wei L et al. Activation of the unfolded protein response contributed to the selective cytotoxicity of oroxylin A in human hepatocellular carcinoma HepG2 cells. Toxicol Lett 2012; 212: 113-125.
38. Liu W, Mu R, Nie FF, Yang Y, Wang J, Dai QS et al. MAC-related mitochondrial pathway in oroxylin-A-induced apoptosis in human hepatocellular carcinoma HepG2 cells. Cancer Lett 2009; 284: 198-207.
39. Wei L, Dai Q, Zhou Y, Zou M, Li Z, Lu N et al. Oroxylin A sensitizes non-small cell lung cancer cells to anoikis via glucose-deprivation-like mechanisms: c-Src and hexokinase II. Biochim Biophys Acta 2013; 1830: 3835-3845.
40. Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci USA 2008; 105: 14447-14452.
41. Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 2010; 143: 802-812.
42. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H et al. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell 2010; 40: 893-904.
43. Alhazzazi TY, Kamarajan P, Joo N, Huang JY, Verdin E, D'Silva NJ et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2011; 117: 1670-1678.
44. Shulga N, Wilson-Smith R, Pastorino JG. Sirtuin-3 deacetylation of cyclophilin D induces dissociation of hexokinase II from the mitochondria. J Cell Sci 2010; 123: 894-902.
45. Kim SH, Lu HF, Alano CC. Neuronal Sirt3 protects against excitotoxic injury in mouse cortical neuron culture. PLoS One 2011; 66: e14731.
46. Li HB, Chen F. Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography. J Chromatogr A 2005; 1074: 107-110.